Key Points
- DexCom insider Kevin Sayer sold 26,759 shares on May 21 at an average price of $72.00, totaling about $1.93 million. The sale was made under a pre-arranged Rule 10b5-1 plan.
- DexCom stock was roughly flat around $72, while the company’s shares have traded between $54.11 and $89.98 over the past year. The stock also sits above both its 50-day and 200-day moving averages.
- The company recently reported better-than-expected quarterly results, with EPS of $0.56 versus $0.47 expected and revenue of $1.19 billion. Analysts remain broadly positive, with a consensus rating of Moderate Buy and an average target price of $82.21.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) insider Kevin Sayer sold 26,759 shares of DexCom stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares of the company's stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Stock Down 0.1%
DXCM stock opened at $72.01 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a fifty day simple moving average of $63.87 and a 200 day simple moving average of $66.18. The firm has a market cap of $27.79 billion, a PE ratio of 30.77, a PEG ratio of 1.19 and a beta of 1.40.
DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.32 EPS. DexCom's quarterly revenue was up 15.0% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of DXCM. Glenmede Trust Co. NA increased its holdings in shares of DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company's stock worth $24,790,000 after purchasing an additional 105,928 shares during the period. Wellington Grp LLC increased its holdings in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock worth $34,000 after purchasing an additional 475 shares during the period. Janus Henderson Group PLC increased its holdings in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock worth $166,077,000 after purchasing an additional 645,534 shares during the period. Centaurus Financial Inc. bought a new position in shares of DexCom during the 1st quarter worth about $943,000. Finally, Tri Locum Partners LP increased its holdings in shares of DexCom by 65.6% during the 1st quarter. Tri Locum Partners LP now owns 698,158 shares of the medical device company's stock worth $43,844,000 after purchasing an additional 276,558 shares during the period. Institutional investors own 97.75% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Truist Financial reiterated a "buy" rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Bank of America dropped their target price on shares of DexCom from $100.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, May 18th. Piper Sandler reiterated an "overweight" rating on shares of DexCom in a report on Thursday, February 5th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the stock a "buy" rating in a report on Monday, May 18th. Finally, Raymond James Financial set a $81.00 target price on shares of DexCom in a report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $82.21.
Get Our Latest Stock Report on DexCom
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
